{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:22:56Z","timestamp":1793197376379,"version":"4.5.0"},"reference-count":416,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jaci.2022.01.025","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T01:44:51Z","timestamp":1644803091000},"page":"1525-1560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":216,"title":["Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A\u00a0Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees"],"prefix":"10.1016","volume":"149","author":[{"given":"Iris M.","family":"Otani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather K.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artemio M.","family":"Jongco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu R.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine E.","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa K.","family":"Tarrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissa","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolan E.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tho Q.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ballow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cunningham-Rundles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mildred","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Barmettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.01.025_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108326","article-title":"The immunologic features of patients with early-onset and polyautoimmunity","volume":"211","author":"Hoyt","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib3","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1177\/0961203313507990","article-title":"Hypogammaglobulinemia in pediatric systemic lupus erythematosus","volume":"22","author":"Lim","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.jaci.2022.01.025_bib4","first-page":"125","article-title":"High prevalence of primary immune deficiencies in children with autoimmune disorders","volume":"29","author":"Barsalou","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12969-015-0050-8","article-title":"Primary complement and antibody deficiencies in autoimmune rheumatologic diseases with juvenile onset: a prospective study at two centers","volume":"13","author":"Sp\u00e2rchez","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jaci.2022.01.025_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency\u2014causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jaci.2022.01.025_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaci.2022.01.025_bib10","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.leukres.2015.10.013","article-title":"Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study","volume":"39","author":"De Angelis","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2022.01.025_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/ACI.0000000000000689","article-title":"Primary immune regulatory disorders: a growing universe of immune dysregulation","volume":"20","author":"Chan","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142205","article-title":"A retrospective longitudinal within-subject risk interval analysis of immunoglobulin treatment for recurrent acute exacerbation of chronic obstructive pulmonary disease","volume":"10","author":"Cowan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.01.025_bib14","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.chest.2020.04.058","article-title":"Serum IgG levels and risk of COPD hospitalization: a pooled meta-analysis","volume":"158","author":"Leitao Filho","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2022.01.025_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.rmed.2017.10.016","article-title":"Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease","volume":"132","author":"Berger","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib16","series-title":"A41 COPD: EPIDEMIOLOGY","first-page":"A1580","article-title":"BAL and serum immunoglobulin G levels are associated with risk for exacerbations, clinical and CT phenotypes, an analysis of SPIROMICS","author":"Putcha","year":"2019"},{"key":"10.1016\/j.jaci.2022.01.025_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172437","article-title":"Antibody deficiency in patients with frequent exacerbations of chronic obstructive pulmonary disease (COPD)","volume":"12","author":"McCullagh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.01.025_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/adc.53.8.631","article-title":"Immunological studies in cystic fibrosis","volume":"53","author":"Turner","year":"1978","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaci.2022.01.025_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198001313020501","article-title":"Hypogammaglobulinemia in patients with cystic fibrosis","volume":"302","author":"Matthews","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ppul.20050","article-title":"Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic","volume":"39","author":"Garside","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaci.2022.01.025_bib21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jcf.2010.12.004","article-title":"Change in IgG and evolution of lung function in children with cystic fibrosis","volume":"10","author":"Proesmans","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jaci.2022.01.025_bib22","doi-asserted-by":"crossref","first-page":"AB158","DOI":"10.1016\/j.jaci.2011.12.353","article-title":"Is common variable immune deficiency common in cystic fibrosis?","volume":"129","author":"Jain","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib23","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A\u00a0meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib24","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1097\/TXD.0000000000000811","article-title":"A prospective observational study of hypogammaglobulinemia in the first year after lung transplantation","volume":"4","author":"Petrov","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.jaci.2022.01.025_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.iac.2018.08.005","article-title":"Secondary hypogammaglobulinemia: an increasingly recognized complication of treatment with immunomodulators and after solid organ transplantation","volume":"39","author":"Kaplan","year":"2019","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2022.01.025_bib26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ecco-jcc\/jjw118","article-title":"Phenotypic and genotypic characterisation of inflammatory bowel disease presenting before the age of 2 years","volume":"11","author":"Kammermeier","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2022.01.025_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-018-8689-9","article-title":"Gastrointestinal disorders associated with primary immunodeficiency diseases","volume":"57","author":"Hartono","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaci.2022.01.025_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.jaci.2022.01.025_bib31","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib33","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.jaci.2013.01.036","article-title":"Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement","volume":"131","author":"Agarwal","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib34","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/phar.2047","article-title":"Comparison of weight-based dosing strategies for intravenous immunoglobulin in patients with hematologic malignancies","volume":"37","author":"Stump","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaci.2022.01.025_bib35","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","article-title":"Prophylactic immunoglobulin therapy in secondary immune deficiency\u2014 an expert opinion","volume":"12","author":"Agostini","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib38","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib39","article-title":"Detrimental association of hypogammaglobulinemia with chronic lung allograft dysfunction and death is not mitigated by on-demand immunoglobulin G replacement after lung transplantation","author":"Lichvar","year":"2018","journal-title":"Prog Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib40","article-title":"Impact of prefilter dilution on IgG removal in membrane-based therapeutic plasma exchange","author":"Cabral","year":"2021","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jaci.2022.01.025_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2249.2012.04594.x","article-title":"Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy","volume":"169","author":"Orange","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/ejh.13078","article-title":"A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency","volume":"101","author":"Benbrahim","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib44","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.intimp.2013.02.021","article-title":"Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients","volume":"15","author":"Shankar","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2022.01.025_bib45","first-page":"256","article-title":"Subcutaneous immunoglobulin replacement therapy in a heart transplant recipient with severe recurrent infections","volume":"7","author":"Carbone","year":"2015","journal-title":"Heart Lung Vessel"},{"key":"10.1016\/j.jaci.2022.01.025_bib46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.15761\/CCRR.1000149","article-title":"Improved outcomes on subcutaneous IgG in patients with humoral immunodeficiency and co-morbid bowel disease","volume":"1","author":"Shah","year":"2015","journal-title":"Clin Case Rep Rev"},{"key":"10.1016\/j.jaci.2022.01.025_bib47","first-page":"55","article-title":"Secondary hypogammaglobulinemia in Waldmann\u2019s disease treated with subcutaneous immunoglobulins","volume":"48","author":"Patuzzo","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000449163","article-title":"Secondary combined immunodeficiency in pediatric patients after the Fontan operation: three case reports","volume":"170","author":"Hlavackova","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.9794\/jspccs.32.432","article-title":"Subcutaneous immunoglobulin (SCIG) home therapy for treatment of hypogammaglobulinemia due to protein-losing enteropathy (PLE) after total cavopulmonary connection","volume":"32","author":"Yamada","year":"2016","journal-title":"Ped Cardiol Card Surg"},{"key":"10.1016\/j.jaci.2022.01.025_bib50","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jaci.2020.06.036","article-title":"Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: lessons from therapeutic modalities targeting Fc\u03b3 receptors","volume":"146","author":"Shock","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib51","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1592\/phco.26.6.813","article-title":"Pharmacokinetics of intravenous immunoglobulin: a systematic review","volume":"26","author":"Koleba","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaci.2022.01.025_bib52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejps.2018.03.007","article-title":"Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: analysis of a phase III, multicentre, prospective, open-label study","volume":"118","author":"Melamed","year":"2018","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.jaci.2022.01.025_bib53","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.3390\/antib9020024","article-title":"Considerations for optimizing dosing of immunoglobulins based on pharmacokinetic evidence","volume":"9","author":"Mahmood","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jaci.2022.01.025_bib54","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/j.jaci.2009.08.040","article-title":"Secondary immunodeficiencies, including HIV infection","volume":"125","author":"Chinen","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib55","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2022.01.025_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaci.2022.01.025_bib57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment\u2014incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.jaci.2022.01.025_bib58","first-page":"1","article-title":"Retrospective analysis of the immunologic evaluation in patients receiving ocrelizumab","volume":"40","author":"Yang","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib59","doi-asserted-by":"crossref","first-page":"AB16","DOI":"10.1016\/j.jaci.2018.12.051","article-title":"Hypogammaglobulinemia in multiple sclerosis patients receiving disease-modifying immunomodulatory agents","volume":"143","author":"Tsao","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib60","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.anai.2019.08.227","article-title":"M255 Persistent hypogammaglobulinemia following obinutuzumab treatment for chronic lymphocytic leukemia","volume":"123","author":"Hauk","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib61","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2016.152272","article-title":"Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma","volume":"102","author":"Grigg","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.01.025_bib62","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1080\/10428194.2018.1515940","article-title":"Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study","volume":"60","author":"Sharman","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.jaci.2022.01.025_bib63","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.01.025_bib64","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.01.025_bib65","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib66","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","article-title":"Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis","volume":"53","author":"Besada","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2022.01.025_bib67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study","volume":"48","author":"Boleto","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.01.025_bib68","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib69","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2022.01.025_bib70","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/rheumatology\/ker106a","article-title":"BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis","volume":"50","author":"Bukhari","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2022.01.025_bib71","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/pbc.24343","article-title":"Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood","volume":"60","author":"Price","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaci.2022.01.025_bib72","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/ciaa127","article-title":"Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune disease receiving rituximab: a retrospective cohort study","volume":"72","author":"Stabler","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib73","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib74","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/pai.1988.2.309","article-title":"Steroid-treated asthmatic patients with low levels of IgG have a normal capacity to produce specific antibodies","volume":"2","author":"Katz","year":"1988","journal-title":"Pediatr Asthma Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib75","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2022.01.025_bib76","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaci.2022.01.025_bib77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2022.01.025_bib78","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jaci.2015.06.035","article-title":"Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long?","volume":"136","author":"Barmettler","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib79","first-page":"347","article-title":"Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis","volume":"33","author":"Roll","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib80","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jaci.2022.01.025_bib82","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2022.01.025_bib83","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A\u00a0narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib84","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.2013.281115","article-title":"FDA: increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2022.01.025_bib85","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2022.01.025_bib86","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib87","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jbspin.2011.11.002","article-title":"Progressive multifocal leukoencephalopathy in autoimmune diseases","volume":"79","author":"Palazzo","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaci.2022.01.025_bib88","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system","volume":"15","author":"Raisch","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaci.2022.01.025_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2019.e00558","article-title":"Chronic enteroviral meningoencephalitis in a patient on rituximab for the treatment of psoriatic arthritis: a case report and brief literature review","volume":"17","author":"Tellez","year":"2019","journal-title":"IDCases"},{"key":"10.1016\/j.jaci.2022.01.025_bib90","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.V99.4.1486","article-title":"Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab","volume":"99","author":"Goldberg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib91","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib92","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00277-007-0397-0","article-title":"Rituximab therapy increased post-transplant cytomegalovirus complications in non-Hodgkin\u2019s lymphoma patients receiving autologous hematopoietic stem cell transplantation","volume":"87","author":"Lee","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib93","first-page":"ECR49","article-title":"Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine\/cyclophosphamide and rituximab for relapsed B cell lymphoma","volume":"91","author":"Hartmann","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.01.025_bib94","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ajh.20200","article-title":"Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy","volume":"77","author":"Isobe","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib95","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184.015k54_1184_1186","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab","volume":"96","author":"Sharma","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2141.2002.03778.x","article-title":"Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma","volume":"119","author":"Song","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib97","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib98","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib99","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaci.2022.01.025_bib100","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/ene.12132","article-title":"Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab","volume":"20","author":"Kim","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jaci.2022.01.025_bib101","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2022.01.025_bib103","unstructured":"Genentech. Ocrevus (ocrelizumab) [package insert]. 2021."},{"key":"10.1016\/j.jaci.2022.01.025_bib104","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.01.025_bib105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.01.025_bib106","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib107","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1203475418811335","article-title":"Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies","volume":"23","author":"Papp","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2022.01.025_bib108","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5152\/eurjrheum.2016.16100","article-title":"Vaccination recommendations for adult patients with rheumatic diseases","volume":"3","author":"Tanr\u0131\u00f6ver","year":"2016","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib110","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib111","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.41734","article-title":"American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib112","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2022.01.025_bib113","doi-asserted-by":"crossref","first-page":"102851","DOI":"10.1016\/j.msard.2021.102851","article-title":"Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment","volume":"50","author":"Smets","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jaci.2022.01.025_bib114","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","article-title":"Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin","volume":"146","author":"Cooper","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00431-006-0222-0","article-title":"Persistent B-cell depletion after rituximab for thrombocytopenic purpura","volume":"166","author":"Bisogno","year":"2007","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaci.2022.01.025_bib116","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/08880010903271697","article-title":"Persistent antibody depletion after rituximab in three children with autoimmune cytopenias","volume":"26","author":"Adeli","year":"2009","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.jaci.2022.01.025_bib117","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","article-title":"Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature","volume":"13","author":"Levy","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2022.01.025_bib118","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.anai.2015.05.007","article-title":"Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy","volume":"115","author":"Palacios","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib119","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune haemolytic anaemia with rituximab","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.01.025_bib120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12969-019-0365-y","article-title":"Rituximab-associated hypogammaglobulinemia in pediatric patients with autoimmune diseases","volume":"17","author":"Khojah","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jaci.2022.01.025_bib121","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaip.2019.07.032","article-title":"Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia","volume":"8","author":"Ottaviano","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.01.025_bib122","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.01.025_bib123","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","article-title":"Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias","volume":"50","author":"Rao","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaci.2022.01.025_bib124","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaci.2021.03.041","article-title":"Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients","volume":"148","author":"Labrosse","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00467-012-2361-z","article-title":"Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?","volume":"28","author":"Delbe-Bertin","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jaci.2022.01.025_bib126","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers7010305","article-title":"Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?","volume":"7","author":"Worch","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2022.01.025_bib127","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/j.1600-6143.2008.02411.x","article-title":"A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation","volume":"8","author":"Zarkhin","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib128","article-title":"Rituximab for children with immune thrombocytopenia: a systematic review","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.01.025_bib129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1574892811666160129110614","article-title":"Incidence of profound hypogammaglobulinemia and infection rate in lymphoma patients following the combination of chemotherapy and rituximab","volume":"11","author":"Filanovsky","year":"2016","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.jaci.2022.01.025_bib130","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1136\/annrheumdis-2014-205246","article-title":"Vaccines and biologics","volume":"73","author":"Ferreira","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib131","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/14760584.2016.1193438","article-title":"Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients","volume":"15","author":"Cheng","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jaci.2022.01.025_bib132","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib133","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1445-5994.1997.tb00934.x","article-title":"Lymphocytopenia in a hospital population--what does it signify?","volume":"27","author":"Castelino","year":"1997","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib134","first-page":"472","article-title":"Hypogammaglobulinemia in asthmatic patients","volume":"68","author":"Hamilos","year":"1992","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jaci.2022.01.025_bib135","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000064258","article-title":"Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone","volume":"128","author":"Kawano","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib136","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s10875-016-0264-7","article-title":"Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency","volume":"36","author":"Wirsum","year":"2016","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib137","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0091-6749(78)90101-X","article-title":"Corticosteroid effect on immunoglobulins","volume":"62","author":"Settipane","year":"1978","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib138","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/0091-6749(78)90134-3","article-title":"The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels","volume":"62","author":"Posey","year":"1978","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib139","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1172\/JCI107455","article-title":"Effects of corticosteroids on immunity in man, I: decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone","volume":"52","author":"Butler","year":"1973","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2022.01.025_bib140","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1182\/blood-2007-11-124156","article-title":"Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors","volume":"112","author":"Sharma","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib141","first-page":"159","article-title":"Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease","volume":"37","author":"Lanzillotta","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib142","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1096\/fj.201500135","article-title":"Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD","volume":"30","author":"Lee","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.jaci.2022.01.025_bib143","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-3476(96)70035-5","article-title":"Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia","volume":"129","author":"Lack","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2022.01.025_bib144","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","article-title":"Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome","volume":"34","author":"Sepkowitz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib145","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/archinte.1995.00430110015002","article-title":"Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk","volume":"155","author":"Sepkowitz","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib146","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1378\/chest.118.3.712","article-title":"Peripheral blood CD4\u00a0+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2022.01.025_bib147","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib148","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s41927-019-0079-2","article-title":"Immunoglobulin abnormalities are frequent in patients with lupus nephritis","volume":"3","author":"Cuadrado","year":"2019","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000229","article-title":"Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis","volume":"4","author":"Smilek","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib150","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib151","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2022.01.025_bib152","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/rheumatology\/ken255","article-title":"Management of hypogammaglobulinaemia occurring in patients with systemic lupus erythematosus","volume":"47","author":"Yong","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2022.01.025_bib153","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1136\/annrheumdis-2016-209133corr1","article-title":"Erratum: Eular\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"76","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib154","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","article-title":"Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib155","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib156","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.anai.2019.07.014","article-title":"Autoimmunity in common variable immunodeficiency","volume":"123","author":"Agarwal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib157","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jaci.2017.05.024","article-title":"Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry","volume":"141","author":"Mayor","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib158","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ACI.0000000000000485","article-title":"Secondary antibody deficiency in neurology","volume":"18","author":"Tallantyre","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib159","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaci.2022.01.025_bib160","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jaci.2022.01.025_bib161","doi-asserted-by":"crossref","first-page":"AB215","DOI":"10.1016\/j.jaci.2019.12.250","article-title":"Hypogammaglobulinemia in patients with neuromyelitis optica (NMO)","volume":"145","author":"Tsao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib162","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.jaci.2022.01.025_bib163","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jaci.2022.01.025_bib164","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.jaci.2022.01.025_bib165","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1191\/1352458503ms926oa","article-title":"Safety and tolerability of cyclophosphamide \u2018pulses\u2019 in multiple sclerosis: a prospective study in a clinical cohort","volume":"9","author":"Portaccio","year":"2003","journal-title":"Mult Scler"},{"key":"10.1016\/j.jaci.2022.01.025_bib166","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1177\/1352458513477229","article-title":"Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients","volume":"19","author":"Selter","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.jaci.2022.01.025_bib167","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s10875-020-00861-z","article-title":"Neurologic conditions and symptoms reported among common variable immunodeficiency patients in the USIDNET","volume":"40","author":"Lee","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib168","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/practneurol-2020-002527","article-title":"Protecting people with multiple sclerosis through vaccination","volume":"20","author":"Reyes","year":"2020","journal-title":"Pract Neurol"},{"key":"10.1016\/j.jaci.2022.01.025_bib169","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s40800-018-0087-y","article-title":"Secondary hypogammaglobulinemia after rituximab for neuromyelitis optica: a case report","volume":"5","author":"Farhat","year":"2018","journal-title":"Drug Saf Case Rep"},{"key":"10.1016\/j.jaci.2022.01.025_bib170","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.S36.002","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis (S36.002)","volume":"90","author":"Stokmaier","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2022.01.025_bib171","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/jama.1980.03310210025020","article-title":"Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis","volume":"244","author":"Wing","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2022.01.025_bib172","first-page":"21","article-title":"The use of intravenous immune globulin in multiple myeloma","volume":"97","author":"Chapel","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib173","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/tid.12424","article-title":"Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma","volume":"17","author":"Park","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib174","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.blre.2017.09.003","article-title":"Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation","volume":"32","author":"Ueda","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaci.2022.01.025_bib175","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2022.01.025_bib176","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12067","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib177","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib178","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib179","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00277-011-1275-3","article-title":"Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications","volume":"90","author":"Blombery","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib180","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaci.2022.01.025_bib181","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"Br Med Bull"},{"key":"10.1016\/j.jaci.2022.01.025_bib182","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"Morrison","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib183","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood.V57.3.418.418","article-title":"Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation","volume":"57","author":"Kay","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib184","first-page":"698","article-title":"Hypogammaglobulinaemia associated with abnormalities of both B and T lymphocytes in patients with chronic lymphatic leukaemia","volume":"39","author":"Hersey","year":"1980","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib185","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1182\/blood.V96.9.3168","article-title":"Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction","volume":"96","author":"Sampalo","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib186","first-page":"283","article-title":"An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL","volume":"30","author":"Dighiero","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib187","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.1994.tb05002.x","article-title":"Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes","volume":"88","author":"Chapel","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib188","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","article-title":"Infections in patients with chronic lymphocytic leukemia treated with fludarabine","volume":"129","author":"Anaissie","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib189","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.40425","article-title":"Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in\u00a0systemic lupus erythematosus patients with associated Sj\u00f6gren\u2019s syndrome: post hoc analyses from the EMBODY trials","volume":"70","author":"Gottenberg","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib190","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib191","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2141.2001.02882.x","article-title":"Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia","volume":"114","author":"Sinisalo","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib192","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.anai.2017.10.022","article-title":"Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib","volume":"120","author":"Jiang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib193","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jaci.2022.01.025_bib194","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib195","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJM199201093260216","article-title":"Prophylactic immune globulin in chronic lymphocytic leukemia","volume":"326","author":"Besa","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib196","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3960\/jslrt.49.9","article-title":"Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP","volume":"49","author":"Takata","year":"2009","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.jaci.2022.01.025_bib197","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.4049\/jimmunol.1004095","article-title":"Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin\u2019s lymphoma patients treated with rituximab-containing regimens","volume":"186","author":"Bedognetti","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib198","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","article-title":"Rituximab blocks protective serologic response to influenza A\u00a0(H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment","volume":"118","author":"Yri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib199","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2141.1995.tb08447.x","article-title":"Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma","volume":"89","author":"Musto","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib200","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/bmt.2013.76","article-title":"Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT","volume":"48","author":"Frangoul","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib201","first-page":"377","article-title":"Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis","volume":"13","author":"Ashihara","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib202","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.bmt.1700624","article-title":"Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation","volume":"19","author":"Koehne","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1700626","article-title":"Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow","volume":"19","author":"Talmadge","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib204","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10428190701742506","article-title":"B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period","volume":"49","author":"Lim","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaci.2022.01.025_bib206","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1704742","article-title":"Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia","volume":"35","author":"Lim","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib207","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.bmt.1705463","article-title":"Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin\u2019s lymphoma","volume":"38","author":"Shortt","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib208","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1097\/MPH.0000000000001340","article-title":"Comparison of immune reconstitution after allogeneic versus autologous stem cell transplantation in 182 pediatric recipients","volume":"41","author":"Wiegering","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jaci.2022.01.025_bib209","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.bbmt.2017.05.005","article-title":"Humoral immune reconstitution kinetics after allogeneic hematopoietic stem cell transplantation in children: a maturation block of IgM memory B cells may lead to impaired antibody immune reconstitution","volume":"23","author":"Abdel-Azim","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib210","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bbmt.2019.01.029","article-title":"Effect of graft-versus-host disease prophylaxis regimens on T and B cell reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"T\u00f6rl\u00e9n","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib211","first-page":"86","article-title":"Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease","volume":"90","author":"Abrahamsen","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.01.025_bib212","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/MOH.0b013e328353bc7d","article-title":"Immune reconstitution after hematopoietic cell transplantation","volume":"19","author":"Bosch","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib213","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2022.01.025_bib214","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14712598.8.5.583","article-title":"Immunological reconstitution after hematopoietic cell transplantation\u2014its relation to the contents of the graft","volume":"8","author":"Storek","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaci.2022.01.025_bib215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.bmt.1705870","article-title":"Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality","volume":"41","author":"Berger","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib216","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/sj.bmt.1705381","article-title":"Rapid helper T-cell recovery above 200 x 10 6\/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation","volume":"37","author":"Kim","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib217","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/(SICI)1096-8652(199702)54:2<131::AID-AJH6>3.0.CO;2-Y","article-title":"Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts","volume":"54","author":"Storek","year":"1997","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib218","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.2011.08913.x","article-title":"Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation","volume":"156","author":"Inaba","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib219","doi-asserted-by":"crossref","first-page":"924","DOI":"10.7326\/0003-4819-114-11-924","article-title":"Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"114","author":"Pohl","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib220","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1086\/313848","article-title":"1999 USPHS\/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus","volume":"30","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib221","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/pbc.25409","article-title":"Hypogammaglobulinemia in children after allogeneic hematopoietic stem cell transplantation: a cytokine mediated immunoglobulin isotype class switch arrest?","volume":"62","author":"Sundin","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaci.2022.01.025_bib222","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.bbmt.2018.01.017","article-title":"Choosing wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group\u2019s list of 5 tests and treatments to question in blood and marrow transplantation","volume":"24","author":"Bhella","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib223","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaci.2022.01.025_bib224","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib226","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaci.2022.01.025_bib227","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2022.01.025_bib228","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib229","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib230","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib231","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib232","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib233","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(\u2212)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2022.01.025_bib234","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2011.08.008","article-title":"Effect of rituximab on human in\u00a0vivo antibody immune responses","volume":"128","author":"Pescovitz","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib236","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1093\/cid\/cis513","article-title":"Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease","volume":"55","author":"Dransfield","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib237","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jama.2016.19627","article-title":"Reevaluation of diagnosis in adults with physician-diagnosed asthma","volume":"317","author":"Aaron","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2022.01.025_bib238","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.alit.2019.10.011","article-title":"Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency","volume":"69","author":"Tiotiu","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2022.01.025_bib239","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4168\/aair.2017.9.6.526","article-title":"Effects of immunoglobulin replacement on asthma exacerbation in adult asthmatics with IgG subclass deficiency","volume":"9","author":"Kim","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2022.01.025_bib240","first-page":"53","article-title":"The response to intravenous immunoglobulin replacement therapy in patients with asthma with specific antibody deficiency","volume":"27","author":"Schwartz","year":"2006","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2022.01.025_bib241","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1445-5994.2003.t01-1-00419.x","article-title":"Role of intravenous immunoglobulin in severe steroid-dependent asthma","volume":"33","author":"Haque","year":"2003","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaci.2022.01.025_bib242","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/clim.1999.4714","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma","volume":"91","author":"Kishiyama","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib243","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0091-6749(99)70424-0","article-title":"Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial","volume":"103","author":"Salmun","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib244","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2222.1998.00214.x","article-title":"Prospective, double-blind, placebo-controlled, multicentre study on the effect of high-dose, intravenous immunoglobulin in children and adolescents with severe bronchial asthma","volume":"28","author":"Niggemann","year":"1998","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.01.025_bib245","first-page":"303","article-title":"Some aspects of immunity in patients with cystic fibrosis","volume":"18","author":"Wallwork","year":"1974","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib246","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0022-3476(84)80946-4","article-title":"Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study","volume":"104","author":"Wheeler","year":"1984","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2022.01.025_bib247","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00007890-200101270-00013","article-title":"Hypogammaglobulinemia in lung transplant recipients","volume":"71","author":"Goldfarb","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2022.01.025_bib248","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1399-3046.2008.01067.x","article-title":"Hypogammaglobulinemia: incidence, risk factors, and outcomes following pediatric lung transplantation","volume":"13","author":"Robertson","year":"2009","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib249","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0022-3476(05)83332-3","article-title":"Advanced lung disease in a patient with cystic fibrosis and hypogammaglobulinemia: response to intravenous immune globulin therapy","volume":"117","author":"Bentur","year":"1990","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2022.01.025_bib250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/adc.2003.026575","article-title":"Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children","volume":"89","author":"Balfour-Lynn","year":"2004","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaci.2022.01.025_bib251","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-3476(89)80804-2","article-title":"Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis","volume":"114","author":"Winnie","year":"1989","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2022.01.025_bib252","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.200510-1609OC","article-title":"Immunoglobulin G levels before and after lung transplantation","volume":"173","author":"Yip","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib253","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/ejcts\/ezt583","article-title":"Effect of hypogammaglobulinemia after lung transplantation: a single-institution study","volume":"45","author":"Ohsumi","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jaci.2022.01.025_bib254","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.healun.2012.10.006","article-title":"Bronchiolitis obliterans syndrome, hypogammaglobulinemia, and infectious complications of lung transplantation","volume":"32","author":"Chambers","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib255","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.healun.2018.04.001","article-title":"Monitoring of early humoral immunity to identify lung recipients at risk for development of serious infections: a multicenter prospective study","volume":"37","author":"Sarmiento","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib256","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/01.TP.0000159136.72693.35","article-title":"Risk factors and outcomes of hypogammaglobulinemia after lung transplantation","volume":"79","author":"Kawut","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2022.01.025_bib257","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194924","article-title":"Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS","volume":"13","author":"Putcha","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.01.025_bib258","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1034\/j.1399-3062.2000.020306.x","article-title":"Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?","volume":"2","author":"Corales","year":"2000","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib259","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1053-2498(00)00331-4","article-title":"Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection","volume":"20","author":"Yamani","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib260","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MOT.0b013e3283186bbc","article-title":"Hypogammaglobulinemia and infection risk in solid organ transplant recipients","volume":"13","author":"Mawhorter","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib261","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/bmj.4.5894.702","article-title":"Serum IgG and renal transplantation","volume":"4","author":"Ku","year":"1973","journal-title":"Br Med J"},{"key":"10.1016\/j.jaci.2022.01.025_bib262","first-page":"57","article-title":"Evolution of immunoglobulin and mannose binding protein levels after renal transplantation: association with infectious complications","volume":"21","author":"Broeders","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.jaci.2022.01.025_bib263","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1111\/j.1600-6143.2012.04192.x","article-title":"Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection","volume":"12","author":"Fern\u00e1ndez-Ruiz","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib264","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/tid.12593","article-title":"Hypogammaglobulinemia and risk of severe infection in kidney transplant recipients","volume":"18","author":"Augusto","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib265","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/00007890-198906000-00007","article-title":"Immunoglobulin abnormalities in renal transplant recipients","volume":"47","author":"Pollock","year":"1989","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2022.01.025_bib266","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0272-6386(88)80161-6","article-title":"Hypogammaglobulinemia in a renal transplant recipient with antiglomerular basement membrane disease","volume":"11","author":"Smolin","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib267","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0041-1345(96)00082-6","article-title":"Life after 20 years with a kidney transplant: redefined disease profiles and an emerging nondiabetic vasculopathy","volume":"29","author":"Braun","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaci.2022.01.025_bib268","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s15010-015-0737-2","article-title":"Potential role of post-transplant hypogammaglobulinemia in the risk of Clostridium difficile infection after kidney transplantation: a case-control study","volume":"43","author":"Orig\u00fcen","year":"2015","journal-title":"Infection"},{"key":"10.1016\/j.jaci.2022.01.025_bib269","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12628","article-title":"Post-transplant hypogammaglobulinemia and risk of infection after kidney transplantation: magnitude matters","volume":"19","author":"Fern\u00e1ndez-Ruiz","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib270","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1399-3062.2003.00035.x","article-title":"Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and azathioprine","volume":"5","author":"Keven","year":"2003","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib271","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1399-0012.2010.01255.x","article-title":"Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon?","volume":"25","author":"Boddana","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib272","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12890-015-0133-9","article-title":"Bronchiectasis diagnosed after renal transplantation: a retrospective multicenter study","volume":"15","author":"Dury","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib273","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/01.tp.0000180531.66518.9e","article-title":"Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes","volume":"81","author":"Doron","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2022.01.025_bib274","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007890-199208000-00015","article-title":"The association of IgA deficiency but not IgG or IgM deficiency with a reduced patient and graft survival following liver transplantation","volume":"54","author":"Van Thiel","year":"1992","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2022.01.025_bib275","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1399-3062.2008.00329.x","article-title":"Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection","volume":"10","author":"Carbone","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib276","first-page":"391","article-title":"Immunoglobulins in liver disease","volume":"27","author":"Zuberi","year":"1977","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.jaci.2022.01.025_bib277","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1600-6143.2010.03400.x","article-title":"Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients","volume":"11","author":"Jordan","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib278","article-title":"Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis, part II: non-kidney transplant","volume":"33","author":"Bourassa-Blanchette","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib279","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/TP.0000000000000339","article-title":"Nonspecific immunoglobulin replacement in lung transplantation recipients with hypogammaglobulinemia: a cohort study taking into account propensity score and immortal time bias","volume":"99","author":"Claustre","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2022.01.025_bib280","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.transproceed.2007.06.050","article-title":"The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections","volume":"39","author":"Carbone","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaci.2022.01.025_bib281","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/tid.12610","article-title":"Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial","volume":"18","author":"Sarmiento","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib282","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103908","article-title":"Intravenous immunoglobulin for hypogammaglobulinemia after lung transplantation: a randomized crossover trial","volume":"9","author":"Lederer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.01.025_bib283","article-title":"Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis","volume":"33","author":"Bourassa-Blanchette","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib284","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.transproceed.2015.12.064","article-title":"Impact of immunoglobulin therapy in intestinal transplant recipients with posttransplantation hypogammaglobulinemia","volume":"48","author":"Poole","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaci.2022.01.025_bib285","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1399-3046.2008.00958.x","article-title":"Intravenous immunoglobulin as rescue therapy for BK virus nephropathy","volume":"13","author":"Sharma","year":"2009","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib286","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1111\/j.1399-3046.2010.01384.x","article-title":"Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients","volume":"16","author":"Anyaegbu","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib287","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.tp.0000181096.14257.c2","article-title":"Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients","volume":"81","author":"Sener","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2022.01.025_bib288","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.transproceed.2015.01.012","article-title":"Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients","volume":"47","author":"Vu","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaci.2022.01.025_bib289","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13300","article-title":"Effects of intravenous immunoglobulin therapy and Fc gamma receptor polymorphisms on BK virus nephropathy in kidney transplant recipients","volume":"22","author":"Moon","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib290","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1399-3062.2010.00512.x","article-title":"Increased viral load after intravenous immunoglobulin therapy for BK virus-associated nephropathy","volume":"12","author":"Maggiore","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib291","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1007\/s10875-021-01111-6","article-title":"Perceptions around lung transplant-associated hypogammaglobulinemia","volume":"41","author":"Lew","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib292","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.chest.2016.10.001","article-title":"Comprehensive care of the lung transplant patient","volume":"152","author":"Adegunsoye","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2022.01.025_bib293","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cld.898","article-title":"Optimizing vaccination in adult patients with liver disease and liver transplantation","volume":"15","author":"Rhee","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jaci.2022.01.025_bib294","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","article-title":"Nephrotic syndrome in adults","volume":"336","author":"Hull","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2022.01.025_bib295","first-page":"144","article-title":"Impaired IgG synthesis in patients with the nephrotic syndrome","volume":"18","author":"Heslan","year":"1982","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jaci.2022.01.025_bib296","first-page":"110","article-title":"Impaired immunoglobulin G production in minimal change nephrotic syndrome in adults","volume":"70","author":"Yokoyama","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib297","first-page":"775","article-title":"Metabolism of radio-iodinated IgG in patients with abnormal serum IgG levels, II: hypogamma-globulinaemia","volume":"9","author":"Wells","year":"1971","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib298","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fped.2019.00287","article-title":"Hypertension in childhood nephrotic syndrome","volume":"7","author":"Shatat","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2022.01.025_bib299","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00467-001-0817-7","article-title":"Serum levels of immunoglobulins and IgG subclasses in steroid sensitive nephrotic syndrome","volume":"17","author":"Kemper","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jaci.2022.01.025_bib300","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ajcp\/92.1.68","article-title":"IgG subclasses in children with nephrotic syndrome","volume":"92","author":"Warshaw","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jaci.2022.01.025_bib301","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3349\/ymj.2010.51.2.239","article-title":"Antibody status in children with steroid-sensitive nephrotic syndrome","volume":"51","author":"Han","year":"2010","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jaci.2022.01.025_bib302","first-page":"308","article-title":"Altered immunoglobulin status in congenital nephrotic syndrome","volume":"25","author":"Harris","year":"1986","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jaci.2022.01.025_bib303","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM198902093200614","article-title":"Gamma globulin deficiency in newborns with congenital nephrotic syndrome","volume":"320","author":"Mathias","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib304","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5414\/CN108835","article-title":"Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome","volume":"85","author":"Fujinaga","year":"2016","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jaci.2022.01.025_bib305","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00467-018-4145-6","article-title":"Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome","volume":"34","author":"Fujinaga","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jaci.2022.01.025_bib306","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.12998\/wjcc.v7.i9.1021","article-title":"Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values","volume":"7","author":"Marzuillo","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jaci.2022.01.025_bib307","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","article-title":"Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome","volume":"35","author":"Parmentier","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jaci.2022.01.025_bib308","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3389\/fimmu.2019.01653","article-title":"Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome","volume":"10","author":"Colucci","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib309","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s10157-020-01858-z","article-title":"Profound effect of post-rituximab mycophenolate mofetil administration for persistent hypogammaglobulinemia in young children with steroid-dependent nephrotic syndrome","volume":"24","author":"Fujinaga","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jaci.2022.01.025_bib310","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0272-6386(12)80899-7","article-title":"Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome","volume":"24","author":"Ogi","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib311","first-page":"680","article-title":"Strongyloides hyperinfection and hypogammaglobulinemia","volume":"12","author":"Seet","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib312","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF02214947","article-title":"Campylobacter jejuni arthritis in secondary amyloidosis","volume":"14","author":"Simon","year":"1995","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib313","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003964.pub3","article-title":"Interventions for preventing infection in nephrotic syndrome","author":"Wu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2022.01.025_bib314","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.anai.2013.05.018","article-title":"Congenital nephrotic syndrome and agammaglobulinemia: a therapeutic dilemma","volume":"111","author":"Payne","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib315","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/039463201402700220","article-title":"Safety and infectious prophylaxis of intravenous immunoglobulin in elderly patients with membranous nephropathy","volume":"27","author":"Molinaro","year":"2014","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jaci.2022.01.025_bib316","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/tri.12833","article-title":"Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study","volume":"29","author":"Luque","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.jaci.2022.01.025_bib317","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ajg.2009.561","article-title":"Protein-losing enteropathy: case illustrations and clinical review","volume":"105","author":"Umar","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2022.01.025_bib318","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0016-5085(81)90506-0","article-title":"Intestinal clearance of alpha 1-antitrypsin. A\u00a0sensitive method for the detection of protein-losing enteropathy","volume":"81","author":"Florent","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2022.01.025_bib319","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005581","article-title":"A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter","volume":"11","author":"Umeno","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jaci.2022.01.025_bib320","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MPG.0000000000001321","article-title":"Pediatric-onset chronic nonspecific multiple ulcers of small intestine: a nationwide survey and genetic study in Japan","volume":"64","author":"Uchida","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaci.2022.01.025_bib321","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MPG.0000000000002567","article-title":"North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease","volume":"70","author":"Kelsen","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaci.2022.01.025_bib322","first-page":"447","article-title":"Administration of intravenous immunoglobulin in two children with hypogammaglobulinaemia due to protein losing enteropathy","volume":"60","author":"De Giacomo","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib323","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/1744666X.2014.902314","article-title":"Secondary antibody deficiency","volume":"10","author":"Duraisingham","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib324","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib325","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15537\/smj.2016.2.13232","article-title":"Intestinal lymphangiectasia in children. A\u00a0favorable response to dietary modifications","volume":"37","author":"Isa","year":"2016","journal-title":"Saudi Med J"},{"key":"10.1016\/j.jaci.2022.01.025_bib326","first-page":"SD03","article-title":"Waldmann\u2019s disease (primary intestinal lymphangiectasia) with atrial septal defect","volume":"11","author":"Aroor","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.jaci.2022.01.025_bib327","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1056\/NEJMoa1615887","article-title":"CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis","volume":"377","author":"Ozen","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib328","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/imr.12726","article-title":"Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms","volume":"287","author":"Pazmandi","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2022.01.025_bib329","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ejhg.2016.5","article-title":"Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations","volume":"24","author":"Stephen","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jaci.2022.01.025_bib330","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1194\/jlr.P075119","article-title":"Identification and characterization of a novel DGAT1 missense mutation associated with congenital diarrhea","volume":"58","author":"Gluchowski","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jaci.2022.01.025_bib331","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0884533612444532","article-title":"Protein-losing enteropathy and the Fontan operation","volume":"27","author":"Johnson","year":"2012","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.jaci.2022.01.025_bib332","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaip.2015.11.034","article-title":"Risk factors and clinical significance of lymphopenia in survivors of the Fontan procedure for single-ventricle congenital cardiac disease","volume":"4","author":"Morsheimer","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.01.025_bib333","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/heart.89.10.1130","article-title":"Acquired combined immunodeficiency associated with protein losing enteropathy complicating Fontan operation","volume":"89","author":"Chakrabarti","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.jaci.2022.01.025_bib334","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00246-015-1294-2","article-title":"Management options and outcomes for neonatal hypoplastic left heart syndrome in the early twenty-first century","volume":"37","author":"Kane","year":"2016","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jaci.2022.01.025_bib335","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00246-020-02468-y","article-title":"Higher incidence of protein-losing enteropathy in patients with single systemic right ventricle","volume":"42","author":"Bernardi","year":"2021","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jaci.2022.01.025_bib336","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1161\/CIR.0000000000000696","article-title":"Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association","volume":"140","author":"Rychik","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaci.2022.01.025_bib337","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1017\/S1047951110001162","article-title":"Rare problems associated with the Fontan circulation","volume":"20","author":"Goldberg","year":"2010","journal-title":"Cardiol Young"},{"key":"10.1016\/j.jaci.2022.01.025_bib338","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1747-0803.2007.00116.x","article-title":"Protein-losing enteropathy after Fontan operation","volume":"2","author":"Rychik","year":"2007","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib339","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0022-5223(98)70406-4","article-title":"Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE Study Group","volume":"115","author":"Mertens","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jaci.2022.01.025_bib340","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0022-5223(96)70051-X","article-title":"Protein-losing enteropathy after the Fontan operation","volume":"112","author":"Feldt","year":"1996","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jaci.2022.01.025_bib341","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jpeds.2015.04.061","article-title":"Immune abnormalities in Fontan protein-losing enteropathy: a case-control study","volume":"167","author":"Magdo","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2022.01.025_bib342","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1747-0803.2011.00568.x","article-title":"Protein-losing enteropathy after the total cavopulmonary connection: impact of intravenous immunoglobulin","volume":"6","author":"Zaupper","year":"2011","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib343","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/jinf.2001.0821","article-title":"Legionella pneumonia and bacteraemia in association with protein-losing enteropathy after Fontan operation","volume":"42","author":"Cheung","year":"2001","journal-title":"J Infect"},{"key":"10.1016\/j.jaci.2022.01.025_bib344","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MPG.0000000000002198","article-title":"Eculizumab is safe and effective as a long-term treatment for protein-losing enteropathy due to CD55 deficiency","volume":"68","author":"Kurolap","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaci.2022.01.025_bib345","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJMc1707173","article-title":"Loss of CD55 in eculizumab-responsive protein-losing enteropathy","volume":"377","author":"Kurolap","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib346","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1161\/CIR.0000000000000535","article-title":"Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the American Heart Association","volume":"136","author":"Lui","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jaci.2022.01.025_bib348","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib349","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","article-title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies","volume":"20","author":"Taylor","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib350","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jaci.2022.01.025_bib351","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","article-title":"Rituximab-associated neutropenia","volume":"47","author":"Dunleavy","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib352","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.01.025_bib353","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.autrev.2015.07.013","article-title":"The mechanistic impact of CD22 engagement with epratuzumab on B cell function: implications for the treatment of systemic lupus erythematosus","volume":"14","author":"D\u00f6rner","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2022.01.025_bib354","first-page":"953","article-title":"Targeting CD22 as a strategy for treating systemic autoimmune diseases","volume":"3","author":"D\u00f6rner","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jaci.2022.01.025_bib355","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.01.025_bib356","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib357","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib358","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.jaci.2022.01.025_bib359","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.01.025_bib360","article-title":"Real world experience of daratumumab: evaluating lymphopenia and adverse events in multiple myeloma patients","volume":"10","author":"Cottini","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaci.2022.01.025_bib361","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and its implications in patients treated with daratumumab: a single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib362","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor\u2013modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib363","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib364","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2022.01.025_bib365","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/asheducation-2005.1.220","article-title":"The ubiquitin proteasome pathway from bench to bedside","volume":"2005","author":"Orlowski","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.jaci.2022.01.025_bib366","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.jaci.2022.01.025_bib368","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/art.1780340805","article-title":"Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A\u00a0forty-eight-week randomized, double-blind trial","volume":"34","author":"Jeurissen","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.01.025_bib369","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10067-013-2483-0","article-title":"Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis","volume":"33","author":"Kogure","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib370","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib371","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar4427","article-title":"Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis","volume":"16","author":"Kapetanovic","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2022.01.025_bib372","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/ard.2011.152983","article-title":"Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice","volume":"70","author":"Ribeiro","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib373","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib374","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s13075-014-0506-0","article-title":"Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases","volume":"16","author":"McMahan","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2022.01.025_bib375","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.30580","article-title":"Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors","volume":"63","author":"Kapetanovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.01.025_bib376","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/vaccines8040769","article-title":"Immune response to vaccination in patients with psoriasis treated with systemic therapies","volume":"8","author":"Chiricozzi","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jaci.2022.01.025_bib377","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jaci.2022.01.025_bib378","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib379","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","author":"Goebeler","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib380","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0022-3565(25)24345-2","article-title":"5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells","volume":"272","author":"Stevens","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2022.01.025_bib381","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0016-5085(89)91569-2","article-title":"Inhibition of antibody secretion by 5-aminosalicylic acid","volume":"96","author":"MacDermott","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2022.01.025_bib382","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/ard.44.10.723-b","article-title":"Hypogammaglobulinaemia and thrombocytopenia associated with sulphasalazine therapy in rheumatoid arthritis","volume":"44","author":"Farr","year":"1985","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib383","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00003495-198600321-00010","article-title":"Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine","volume":"32","author":"Farr","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2022.01.025_bib384","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8095695","article-title":"Risk factors and adverse events poorly predict infections and hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab","volume":"2016","author":"Besada","year":"2016","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib385","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1172\/JCI107031","article-title":"The effect of\u00a0azathioprine on gammaglobulin synthesis in man","volume":"51","author":"Levy","year":"1972","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2022.01.025_bib386","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"St\u0119pnicki","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.jaci.2022.01.025_bib387","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/jclinpath-2019-206235","article-title":"Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID)","volume":"73","author":"Ponsford","year":"2020","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jaci.2022.01.025_bib388","first-page":"1","article-title":"Clozapine is associated with secondary antibody deficiency","volume":"214","author":"Ponsford","year":"2018","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaci.2022.01.025_bib389","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/ACI.0000000000000592","article-title":"Clozapine-associated secondary antibody deficiency","volume":"19","author":"Ponsford","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib390","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1440-1819.1998.tb00983.x","article-title":"Hypogammaglobulinemia during antipsychotic therapy","volume":"52","author":"Abe","year":"1998","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jaci.2022.01.025_bib392","first-page":"828","article-title":"Persistent immunoglobulin deficiency after prednisolone and antiepileptic therapy in a C2 deficient patient with lupus-like syndrome","volume":"11","author":"Woo","year":"1984","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib393","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/00365540260348662","article-title":"Reversible panhypogammaglobulinemia associated with phenytoin treatment","volume":"34","author":"Pereira","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib394","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0091-6749(86)90353-2","article-title":"Permanent intrinsic B cell immunodeficiency caused by phenytoin hypersensitivity","volume":"77","author":"Guerra","year":"1986","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib395","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archinte.1989.00390060133029","article-title":"Reversible common variable immunodeficiency syndrome induced by phenytoin","volume":"149","author":"Travin","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib396","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/archderm.1983.01650290055017","article-title":"Erythroderma, hypogammaglobulinemia, and T-cell lymphocytosis. Occurrence following therapy with phenytoin","volume":"119","author":"Lillie","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2022.01.025_bib397","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198202183060707","article-title":"Transient antibody deficiency and abnormal t-suppressor cells induced by phenytoin","volume":"306","author":"Dosch","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib398","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.anai.2019.10.019","article-title":"Carbamazepine-induced B-cell aplasia: overlooked and overtreated","volume":"124","author":"Wong","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib399","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.seizure.2011.12.013","article-title":"Carbamazepine-induced hypogammaglobulinemia","volume":"21","author":"Ozaras","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.jaci.2022.01.025_bib400","first-page":"6","article-title":"Carbamazepine-induced interstitial pneumonitis associated with pan-hypogammaglobulinemia","volume":"5","author":"Gon\u00e7alves","year":"2012","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaci.2022.01.025_bib401","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2010.3535","article-title":"Carbamazepine-induced agammagloblinaemia clinically mimicking diffuse panbronchiolitis","volume":"2011","author":"Hoshino","year":"2011","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaci.2022.01.025_bib402","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2169\/internalmedicine.49.3087","article-title":"B cell aplasia and hypogammaglobulinemia after carbamazepine treatment","volume":"49","author":"Yamamoto","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib403","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.2006.063842","article-title":"Secondary bronchiolitis obliterans organising pneumonia in a patient with carbamazepine-induced hypogammaglobulinemia","volume":"2009","author":"Tamada","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaci.2022.01.025_bib404","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/jnnp.2006.090266","article-title":"Recurrent herpes simplex virus encephalitis secondary to carbamazepine induced hypogammaglobulinaemia","volume":"78","author":"Rice","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jaci.2022.01.025_bib405","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0301-0546(04)79233-2","article-title":"Carbamazepine induced transient monoclonal gammopathy and immunodeficiency","volume":"32","author":"Moreno-Ancillo","year":"2004","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2022.01.025_bib406","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1059-1311(03)00086-4","article-title":"Carbamazepine-induced IgG1 and IgG2 deficiency associated with B cell maturation defect","volume":"13","author":"Go","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.jaci.2022.01.025_bib407","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1590\/S0041-87812001000600006","article-title":"Secondary hypogammaglobilinemia after use of carbamazepine: case report and review","volume":"56","author":"Castro","year":"2001","journal-title":"Rev Hosp Clin Fac Med Sao Paulo"},{"key":"10.1016\/j.jaci.2022.01.025_bib408","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/jnnp.60.4.459","article-title":"Hypogammaglobulinaemia with absent B lymphocytes and agranulocytosis after carbamazepine treatment","volume":"60","author":"Spickett","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jaci.2022.01.025_bib409","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10072-012-1153-3","article-title":"Valproate-induced panhypogammaglobulinemia","volume":"34","author":"Eom","year":"2013","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jaci.2022.01.025_bib410","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.braindev.2016.06.006","article-title":"Immunoglobulin A\u00a0deficiency following treatment with lamotrigine","volume":"38","author":"Maruyama","year":"2016","journal-title":"Brain Dev"},{"key":"10.1016\/j.jaci.2022.01.025_bib415","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/ctr.12458","article-title":"Does increasing immunoglobulin levels impact survival in solid organ transplant recipients with hypogammaglobulinemia?","volume":"28","author":"Florescu","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib416","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.healun.2004.11.016","article-title":"The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study","volume":"24","author":"Yamani","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib417","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.healun.2007.07.010","article-title":"Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer?","volume":"26","author":"Mu\u00f1oz","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib418","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A\u00a0randomized, controlled clinical trial","volume":"319","author":"Gale","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.01.025_bib419","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors","volume":"73","author":"Griffiths","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.01.025_bib420","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.1994.tb01874.x","article-title":"Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin","volume":"53","author":"Jurlander","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib421","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","article-title":"Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia\u00a0and secondary hypogammaglobulinaemia","volume":"17","author":"Boughton","year":"1995","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.jaci.2022.01.025_bib422","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1159\/000227231","article-title":"Effect of various doses of intravenous polyclonal IgG on in\u00a0vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma","volume":"50","author":"Sklenar","year":"1993","journal-title":"Oncology"},{"key":"10.1016\/j.jaci.2022.01.025_bib423","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.01.025_bib424","first-page":"160","article-title":"Immunoglobulin replacement therapy by self-infusion at home","volume":"73","author":"Chapel","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2022.01.025_bib425","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.transproceed.2005.09.153","article-title":"Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation","volume":"37","author":"Sarmiento","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaci.2022.01.025_bib426","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-3062.2006.00136.x","article-title":"IgG monitoring to identify the risk for development of infection in heart transplant recipients","volume":"8","author":"Sarmiento","year":"2006","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaci.2022.01.025_bib427","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.healun.2016.10.004","article-title":"Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: a multicenter prospective study","volume":"36","author":"Sarmiento","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaci.2022.01.025_bib428","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492200152X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492200152X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:36:28Z","timestamp":1758792988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167492200152X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":416,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S009167492200152X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.01.025","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A\u00a0Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}